Preventive focuses on applying CRISPR-based gene-editing to human embryos so that couples carrying serious hereditary conditions can have children free of those diseases. The company’s scientists plan to work directly with affected couples, editing the embryos’ DNA to remove the pathogenic mutation before implantation. Because clinical embryo editing is illegal in the United States, the firm is evaluating the United Arab Emirates, where such procedures are permitted, as a location for its first human trials. Preventive positions its approach as a preventive cure for the more than 300 million people worldwide who live with genetic disorders, arguing that fixing mutations before birth is simpler than treating disease later in life. The project has generated significant ethical debate, with critics citing medical risks and limited scientific understanding of long-term effects. No revenue, user, or cost metrics have been disclosed; the company is still in its pre-commercial research phase.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025